In collaboration with the University of Southampton, Synairgen (both Southampton, UK) have announced positive results from their recent trial of SNG001, a novel protein based COVID-19 drug.
Browsing: Basic > Drug Development
In a collaborative study between the University of South Florida (USF Health; FL, USA) and the University of Arizona College of Pharmacy (AZ, USA), several existing drugs have been identified as potential therapies for COVID-19.
The emergence and global spread of SARS-CoV-2 has prompted scientific study on an unprecedented scale, with an urgent need for…
Harvard’s Wyss Institute is leveraging its unique technology innovation capabilities to develop diagnostic, therapeutic, and vaccine interventions for COVID-19 at lightning speed.
Researchers have accurately profiled the immune response to COVID-19 in critically ill patients, allowing them to identify six inflammatory molecules as potential targets for COVID-19 treatment.
Rebiotix (MN, USA) recently announced positive preliminary results from an ongoing clinical trial investigating the use of an investigational microbiota-based formulation, RBX2660, for the reduction of C. diff infection.
Take a look behind the scenes of a recent Future Virology paper, titled ‘Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: Let the…
Researchers from Princeton University have uncovered an antibiotic molecule capable of killing both Gram-negative and Gram-positive bacteria using two simultaneous mechanisms, while also avoiding antibiotic resistance.
A drug repurposing survey has identified 30 existing drugs, previously approved for treatment in other diseases, that could be successful in treating COVID-19.